|
[Objective] To study the peripheral blood of breast cancer patients, in tumor tissue TCRαβ/γδ/δ1/δ2 and CXCR4, CCR5 expression levels in order to analyze the expression characteristics and influencing factors; resolve TCRαβ/γδ/δ1/δ2 cells and chemokines by body subpopulations of CXCR4, CCR5 correlation function, expression characteristics and their association with disease; certain theoretical basis for further experimental and clinical applications of targeted therapy for tumors of the biological immune. 【Methods】 peripheral blood by flow cytometry (flow cytometry FCM), detected 30 cases of breast cancer patients before and after surgery in TCRαβ, TCRγδ TCRδ1 TCRδ2, CXCR4, CCR5, cytokines (IL-2, IL-4 of IL- 5, IL-10, TNFα, INF-γ), CA-125, CA-153, and lymphocyte immune function (CD3, CD4, CD8, CD4/CD8, NK, CIK) expression levels, and 30 cases of benign breast tumor control; simultaneous detection of the normal breast tissue in the resected specimen, organizations and breast tissue adjacent breast TCRαβ the TCRγδ TCRδ1, TCRδ2, CXCR4, CCR5 expression situation, combined with clinical and pathological features, analysis in the peripheral blood of breast cancer patients, tumor tissue TCRαβ/γδ/δ1/δ2 and CXCR4, CCR5 expression levels. 【Results】 1.30 cases of breast cancer in patients with peripheral blood TCRγδ TCRδ1 the TCRδ2 expression levels in peripheral blood were 8.73 ± 7.57%, 7.82 ± 5.47% and 6.81 ± 6.32%, compared with benign control group significantly increased (P = 0.000); chemokines in peripheral blood factor receptor CCR5, CXCR4 expression levels were 26.64 ± 5.46% and 41.10 ± 8.08%, compared with benign control group was significantly higher (P = 0.000): 2. TCRγδ expression levels of organizations and breast cancer tissue in normal breast tissue, breast side comparison: 6.78 ± 5.48% in normal breast tissue, breast cancer adjacent tissues was 23.58 ± 14.88%, 17.30 ± 18.16% in Breast Cancer the difference was statistically significant (P <0.05); breast cancer adjacent tissues and breast tissue comparison, the difference was not statistically significant; organization TCRδ1 expression levels in normal breast tissue, breast side and breast cancer tissue in comparison: normal breast tissue for 8.39 ± 7.51%, 23.77 ± 15.00% for breast cancer adjacent tissues, breast cancer tissue to 11.65 ± 11.07%, the difference was statistically significant (P <0.05); adjacent tissues and breast cancer and breast cancer tissue comparison The difference was statistically significant (P <0.05); organization TCRδ2 expression levels in normal breast tissue, breast side and breast cancer tissue compared: 6.09 ± 6.24% in normal breast tissue, breast cancer adjacent tissues was 18.44 ± 16.35% , in breast cancer tissue was 8.16 ± 7.03%, the difference was statistically significant (P <0.05); adjacent tissues and breast cancer and breast cancer tissue comparison, the difference was statistically significant (P <0.05), the expression of adjacent tissues higher than the expression in the cancer tissue; CCR5 expression levels in normal breast tissue, breast cancer adjacent tissues and breast cancer tissues were 10.00 ± 1.11%, 23.63 ± 3.41%, 53.34 ± 7.50%; CXCR4 expression levels were 12.57 ± 2.45%, 36.28 ± 6.13%, 67.26 ± 3.86%; expression both in the organization for the breast cancer tissue than breast next to organizations, breast cancer than in normal breast tissue adjacent tissues express significant change The difference was statistically significance (P <0.001); breast cancer patients with peripheral blood TCRδ1 TCRδ2 expression level and primary tumor size, lymph node metastasis, tumor marker CA-125 and CA-153 expression comparison results TCRδ2 expression level and primary tumor size was statistically significant (P <0.05): TCRαβ, TCRγδ, TCRδ1,, TCRδ2 surgery before and after difference was statistically significant (P <0.05); breast cancer organization in TCRαβ, TCRγδ TCRδ1 lymph node metastasis, the CA-125 and CA-153 expression was not statistically significant (P> 0.05); CXCR4, CCR5 expression levels in the peripheral blood of patients with breast cancer and breast cancer tissue and tumor primary foci size, lymph node metastasis, preoperative and postoperative property CA-125 and CA-153 tumor marker expression results of the comparison was statistically significant (P <0.05); 6. peripheral blood of breast cancer patients with CXCR4, CCR5, TCRδ1, TCRδ2 express level were related to each other, the peripheral blood of breast cancer patients with CXCR4 and CCR5 expression levels were positively correlated (P <0.05); TCRδ1 TCRδ2 radiate high expression of chemokines in the peripheral blood of breast cancer patients (P <0.05); Factor Receptor CXCR4 CCR5 expression levels TCRδ1, TCRδ2 radiate high expression (P <0.05); CXCR4, CCR5 expression levels in breast cancer tissue related high CXCR4 expression, CCR5 also showed a high expression (P <0.05); breast cancer peripheral blood of patients with CXCR4, CCR5 expression levels of breast cancer organization in CXCR4, CCR5 expression levels were positively correlated (P <0.05); TCRδ1, TCRδ2 expression levels in the peripheral blood of patients with breast cancer and breast cancer tissue related, both with the showed a high expression in peripheral blood of breast cancer patients (P <0.05): TCRγδ with breast cancer organization TCRγδ expression levels were positively correlated (P <0.05). [Conclusion] in peripheral blood of breast cancer patients in TCRγδ TCRδ1 TCRδ2 and CXCR4, CCR5 radiate high expression was significantly higher than that of the benign group; cancer tissue in the tumor tissue and cancer tissue was higher than normal tissue. Their expression in the peripheral blood of patients with breast cancer and breast cancer tissue; and their primary tumor size, lymph node metastasis, tumor marker CA-125 and CA-153 expression, the result was statistically significant new target, they may be associated with the occurrence and metastasis of breast cancer have a certain role in promoting the growth and development of breast cancer, can be used as an indicator to predict tumor metastasis and prognostic evaluation, is expected to become cancer treatment, for breast cancer molecular targeted therapy to provide some new clues and ideas.
|